首页|美国FDA药物临床试验研发主体合规检查信息公开情况的介绍和启示

美国FDA药物临床试验研发主体合规检查信息公开情况的介绍和启示

扫码查看
美国FDA在药物临床试验研发主体合规检查信息的公开及数据库建设方面有着较为成熟的经验.本文对美国FDA管理和公开药物临床试验研发主体合规检查信息的方式进行系统介绍,并结合我国监管现状,为我国药品监管部门建立规范化的合规检查信息数据库、提高药物临床试验研发主体合规检查信息的可及性提出建议.
Introduction to FDA's disclosure of compliance inspection information of research and development entities of drug clinical trials and its implication for China
The Food and Drug Administration(FDA)of the United States has mature experience in the disclosure of compliance inspection information and database construction for research and development entities of drug clinical trials.This article provides a systematic introduction to this system of FDA.Based on the current regulatory status in China,suggestions were proposed for the drug regulatory authorities to establish a standardized compliance inspection information database and improve the accessibility of compliance inspection information of research and development entities of drug clinical trials.

drug clinical trialcompliance inspectionclinical investigatordrug clinical institute

刘艺迪、何辉、周刚

展开 >

国家药品监督管理局药品审评中心,北京 100076

药物临床试验 合规检查 临床研究者 药物临床试验机构

2024

中国新药杂志
中国医药科技出版社 中国医药集团总公司 中国药学会

中国新药杂志

CSTPCD北大核心
影响因子:1.039
ISSN:1003-3734
年,卷(期):2024.33(2)
  • 6